ClinicalTrials.gg
RecruitingNCT06997627Updated Jul 10, 2025

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

A Phase 1/2 interventional study of GC3111B and Boostrix® in Tetanus-diphtheria-acellular Pertussis (Tdap), sponsored by GC Biopharma Corp. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by GC Biopharma Corp · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Diphtheria with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Diphtheria · Korea, Republic of.

Planned enrollment
14th of 16
120 · median 340
Started
2025
the only one that year
Phase 1/2
2 of 19
1 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
GC Biopharma Corp

Among the 19 studies in Diphtheria with a site in Korea, Republic of, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 19th registered.

Diphtheria

268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.

Browse Diphtheria studies →

Open to participants now

1 of the 19 studies in Diphtheria with a site in Korea, Republic of is open now.

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diphtheria with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.

03

Conditions studied

  • Tetanus-diphtheria-acellular Pertussis (Tdap)
04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 19 to 64 years old as of the date of written consent.
  • Individuals with no history of vaccination with a vaccine containing diphtheria, tetanus, or pertussis antigens within the past 2 years prior to administration of the product.

Exclusion criteria

Exclusion Criteria:

  • Individuals who have received a vaccine within 4 weeks prior to administration of the product.
  • Individuals with a history of Tdap vaccination prior to administration of the investigational product.
  • Pregnant and breastfeeding women.
  • Individuals who have participated in other clinical trials involving investigational products/devices within 6 months prior to administration of the investigational product.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    GC3111B

    Participants randomized to receive a single dose of GC3111B vaccine.

    Biological: GC3111B

  • Active comparator
    Boostrix®

    Participants randomized to receive a single dose of Boostrix® vaccine.

    Biological: Boostrix®

Interventions

  • BiologicalGC3111B

    0.5 mL, Intramuscular injection

  • BiologicalBoostrix®

    0.5 mL, Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Solicited adverse events occurring by day 14 after administration of the investigational product

    Time frame: 14 days after administration of the IP

  2. Unsolicited adverse events occurring by day 28 after administration of the investigational product

    Time frame: 28 days after administration of the IP

  3. Acute adverse events occurring within 30 minutes after administration of the investigational product

    Time frame: 30 minutes after administration of the IP

  4. Serious adverse events (SAE) and adverse events of special interest (AESI) occurring up to 180 days after administration of the investigational product

    Time frame: 180 days after administration of the IP

  5. Clinically significant findings in vital signs, laboratory tests, 12-lead electrocardiograms, and physical examinations

    Time frame: 28 days after administration of the IP

Secondary outcomes

  1. Antibody rates for diphtheria and tetanus on day 28 after administration of the investigational product

    Time frame: 28 days after administration of the IP

  2. Boosting response rates for diphtheria, tetanus, and pertussis on day 28 after administration of the investigational product

    Boosting response rate: 1) If less than 0.1 IU/ml before vaccination, it should be 0.4 IU/ml or higher after the vaccination, or 2) if not less than 0.1 IU/ml before vaccination, it should be 4 times or higher after the vaccination.

    Time frame: 28 days after administration of the IP

  3. Geometric mean concentrations (GMC) of antibodies against diphtheria, tetanus, and pertussis antitoxins (anti-PT, anti-FHA, anti-PRN) on day 28 after administration of the investigational product

    Time frame: 28 days after administration of the IP

07

Study locations

1 of 1 sites recruiting
  • The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital
    Seoul, 1021, South Korea
    Recruiting
    • Junghyun Choi, MD, PhD. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for May 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 30, 2025
StartActual
Jun 5, 2025
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06997627
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
May 30, 2025
Start date
Jun 5, 2025
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Jul 10, 2025

Study contacts

Minji Ko
Contact
minji.ko@gccorp.com
+82-31-260-9143
Sujin Lee
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion